港股異動 | 亞盛醫藥-B(6855.HK)升近9% 年度收益達1250萬元 產業基地將於今年投產
格隆匯4月1日丨亞盛醫藥-B(6855.HK)尾盤漲幅擴大至8.73%,報33港元,暫成交4278萬港元,總市值83.4億港元。亞盛醫藥-B昨日(31日)公佈年度業績,2020年度公司收益為1250萬元,收益乃來自提供予客户的非重複性研發服務及來自一名客户的知識產權許可費收入。值得注意的是,虧損淨額由2019年度的14.81億元減少至6.78億元。2020年,亞盛醫藥在各個業務領域均取得長足進展,鑄就了多個意義重大的里程碑。全年研發開支5.65億元,全球研發中心及產業基地將於2021年投產。此外,亞盛醫藥於2020年12月正式獲納入深港通下港股通名單。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.